DERMAPHARM HLDG INH O.N./ DE000A2GS5D8 /
| 2024-05-06 11:38:37 AM | Chg. -0.250 | Volume | Bid11:38:38 AM | Ask11:41:38 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 33.250EUR | -0.75% | 2,708 Turnover: 91,164.700 |
33.150Bid Size: 378 | 33.350Ask Size: 245 | 1.83 bill.EUR | 2.59% | 29.31 |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 1.16 EUR | -53.41% |
| EPS Diluted: | - EUR | -53.41% |
| Revenues per Share: | 21.09 EUR | 10.79% |
| Book Value per Share: | 10.01 EUR | 1.43% |
| Cash Flow per Share: | 4.08 EUR | -23.94% |
| Dividend per Share: | 0.88 EUR | -16.19% |
| Total | in mill. | |
| Revenues: | 1,135.35 EUR | 10.79% |
| Net Income: | 58.11 EUR | -56.18% |
| Operating Cash Flow: | 219.42 EUR | - |
| Cash and Cash Equivalents: | 158.72 EUR | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 29.31 | 36.52 |
| P/S Ratio: | 1.61 | 2.01 |
| P/BV ratio: | 3.40 | 4.23 |
| P/CF Ratio: | 8.34 | 10.39 |
| PEG: | -0.55 | -0.68 |
| Earnings Yield: | 3.41% | 2.74% |
| Dividend Yield: | 2.59% | 2.08% |
| Market Capitalization | ||
| Market Capitalization: | 1.83 bill. EUR | 2.28 bill. EUR |
| Free Float Market Cap.: | - EUR | - EUR |
| Market Cap. / Employee: | 523,465.8279 EUR | 652,176.8373 EUR |
| Shares Outstanding: | 53.84 mill. | |
Profitability
| Gross Profit Margin: | - |
| EBIT Margin: | 16.11% |
| Net Profit Margin: | 5.12% |
| Return on Equity: | 10.78% |
| Return on Assets: | 2.69% |
Financial Strength
| Liquidity I / Cash Ratio: | 40.24% |
| Liquidity II / Quick Ratio: | 63.29% |
| Liquidity III / Current Ratio: | 159.83% |
| Debt / Equity Ratio: | 300.72% |
| Dynam. Debt / Equity Ratio: | 738.98% |
Efficiency
| Employees: | 3,497 |
| Personal Expenses / Employee: | - EUR |
| Revenues / Employee: | 324,664.00 EUR |
| Net Income / Employee: | 16,617.10 EUR |
| Total Assets / Employee: | 617,863.88 EUR |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | IFRS |
| Currency: | EUR |
